SPRO

Spero Therapeutics, Inc. [SPRO] Stock Forecast

Q: What is Spero Therapeutics, Inc. stock symbol ?

Spero Therapeutics, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol SPRO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SPRO Stock Summary

Earnings have grown 99.13% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

SPRO has more than 2 years of cash runway (28 months)

Earnings are expected to fall -100% next year

Profit margins (-0.01%) are lower than the previous year (0.24%)

In the News

SPRO Financial details

Company Rating

Buy

Market Cap

88.35M

Income

23.77M

Revenue

98.83M

Book val./share

2.02

Cash/share

1.44

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2024

P/E

-117.85

Forward P/E

PEG

8.72

P/S

1.06

P/B

1.43

P/C

0.98

P/FCF

2.68

Quick Ratio

3.8

Current Ratio

4.01

Debt / Equity

0.05

LT Debt / Equity

0.04

EPS (TTM)

0.45

EPS next Y

EPS next Q

EPS this Y

-133.59%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

82.78%

Revenue Q/Q

181.97%

EPS Q/Q

-1695.39%

SMA20

SMA50

100%

SMA100

100%

Inst Own

24.9%

Inst Trans

0.91%

ROA

-1%

ROE

-1%

ROC

-0.04%

Gross Margin

75%

Oper. Margin

-4%

Profit Margin

-1%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.99-1.995

52W High

52W Low

RSI

Rel Volume

1.13

Avg Volume

317.01K

Volume

358.55K

Perf Week

-17.54%

Perf Month

-15.06%

Perf Quarter

38.24%

Perf Half Y

21.55%

Beta

0.575

Volatility

0.07%, 0.11%

Prev Close

-4.08%

Price

1.41

Change

-6%

SPRO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.26	0.42	0.59	1.29	1.84
Net income per share	-3.31	-3.46	-2.96	-1.28	0.43
Operating cash flow per share	-2.75	-3.84	-2.08	-0.21	-0.63
Free cash flow per share	-2.77	-3.84	-2.08	-0.21	-0.63
Cash per share	4.52	5.67	4.74	2.9	1.45
Book value per share	4.11	5.9	2.86	2.02	2.03
Tangible book value per share	4.11	5.9	2.86	2.02	2.03
Share holders equity per share	4.11	5.9	2.86	2.02	2.03
Interest debt per share	0.31	0.35	0.3	0.25	0.11
Market cap	174.7M	434.07M	494.64M	65.02M	77.47M
Enterprise value	150.52M	356.7M	389.39M	-37.44M	6.68M
P/E ratio	-2.9	-5.6	-5.42	-1.35	3.4
Price to sales ratio	36.84	46.52	27.09	1.34	0.8
POCF ratio	-3.49	-5.05	-7.69	-8.41	-2.35
PFCF ratio	-3.47	-5.05	-7.69	-8.41	-2.35
P/B Ratio	2.34	3.29	5.6	0.86	0.72
PTB ratio	2.34	3.29	5.6	0.86	0.72
EV to sales	31.74	38.23	21.33	-0.77	0.07
Enterprise value over EBITDA	-2.38	-4.51	-4.46	1.98	0.33
EV to operating cash flow	-3.01	-4.15	-6.05	4.84	-0.2
EV to free cash flow	-2.99	-4.15	-6.06	4.84	-0.2
Earnings yield	-0.34	-0.18	-0.18	-0.74	0.29
Free cash flow yield	-0.29	-0.2	-0.13	-0.12	-0.43
Debt to equity	0.07	0.06	0.08	0.09	0.05
Debt to assets	0.05	0.05	0.04	0.05	0.03
Net debt to EBITDA	0.38	0.98	1.2	5.41	-3.52
Current ratio	3.08	8.85	8.46	5.04	3.53
Interest coverage	0	0	-45.35	-16.2	0
Income quality	0.82	1.1	0.72	0.17	-1.45
Dividend Yield	0	0	0.1	0.84	0
Payout ratio	0	0	-0.52	-1.13	0
Sales general and administrative to revenue	3.29	2.3	2.28	0.75	0.26
Research and developement to revenue	13.87	7.18	3.53	0.98	0.53
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0	0	0	0
Capex to revenue	-0.07	-0.02	0	0	0
Capex to depreciation	-0.42	-0.21	0.06	0	0
Stock based compensation to revenue	0.8	0.52	0.52	0.19	0.08
Graham number	17.5	21.44	13.78	7.62	4.44
ROIC	-0.73	-0.53	-0.87	-0.49	0.15
Return on tangible assets	-0.57	-0.51	-0.53	-0.38	0.13
Graham Net	2.77	4.65	2.12	1.56	0.74
Working capital	55.38M	112.56M	139.2M	87.46M	94.06M
Tangible asset value	74.57M	132.04M	88.29M	75.93M	106.89M
Net current asset value	50.52M	105.5M	75.09M	60.24M	55.71M
Invested capital	0.07	0.06	0.08	0.09	0.05
Average receivables	4.92M	7.36M	4.41M	1.86M	25.89M
Average payables	3.88M	2.65M	1.13M	859K	997.5K
Average inventory	-11.07M	-12.8M	-6.12M	-2.23M	-2.23M
Days sales outstanding	657.8	241.61	52.8	8.14	191.29
Days payables outstanding	23.01	6.29	359.77	145.58	1.37K
Days of inventory on hand	-74.19	-66.67	0	-1.05K	0
Receivables turnover	0.55	1.51	6.91	44.81	1.91
Payables turnover	15.86	58.01	1.01	2.51	0.27
Inventory turnover	-4.92	-5.47	0	-0.35	0
ROE	-0.81	-0.59	-1.03	-0.63	0.21
Capex per share	-0.02	-0.01	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.95	0.01	0.01	0.48	1.36
Net income per share	0.55	-0.23	-0.23	-0.06	0.97
Operating cash flow per share	0.91	-0.24	-0.35	0.3	-0.33
Free cash flow per share	0.91	-0.24	-0.35	0.3	-0.33
Cash per share	2.24	1.83	1.48	1.78	1.44
Book value per share	1.56	1.23	1.04	1.02	2.02
Tangible book value per share	1.56	1.23	1.04	1.02	2.02
Share holders equity per share	1.56	1.23	1.04	1.02	2.02
Interest debt per share	0.14	0.1	0.12	0.11	0.1
Market cap	84.28M	76.16M	76.23M	63.78M	77.91M
Enterprise value	-18.18M	-13.71M	4.65M	-24.21M	7.12M
P/E ratio	0.79	-1.55	-1.6	-4.97	0.38
Price to sales ratio	1.82	102.92	96.74	2.5	1.08
POCF ratio	1.89	-5.93	-4.11	4.01	-4.45
PFCF ratio	1.9	-5.93	-4.11	4.01	-4.45
P/B Ratio	1.11	1.17	1.39	1.19	0.73
PTB ratio	1.11	1.17	1.39	1.19	0.73
EV to sales	-0.39	-18.52	5.9	-0.95	0.1
Enterprise value over EBITDA	-0.71	1.04	-0.39	12.52	0.15
EV to operating cash flow	-0.41	1.07	-0.25	-1.52	-0.41
EV to free cash flow	-0.41	1.07	-0.25	-1.52	-0.41
Earnings yield	0.32	-0.16	-0.16	-0.05	0.66
Free cash flow yield	0.53	-0.17	-0.24	0.25	-0.22
Debt to equity	0.09	0.1	0.11	0.11	0.05
Debt to assets	0.05	0.06	0.06	0.05	0.03
Net debt to EBITDA	-3.97	6.83	6.06	45.5	-1.45
Current ratio	5.04	4.42	5.1	4.01	3.53
Interest coverage	10.82K	14.8	0	0	0
Income quality	1.66	0.97	1.56	-4.97	-0.34
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.14	9.89	7.74	0.22	0.09
Research and developement to revenue	0.33	12.13	12.07	0.64	0.23
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1	0	0	0	0
Stock based compensation to revenue	0.05	2.93	2.36	0.07	0.03
Graham number	4.39	2.55	2.31	1.18	6.62
ROIC	0.29	-0.17	-0.19	0.04	0.42
Return on tangible assets	0.21	-0.11	-0.12	-0.03	0.28
Graham Net	1.21	0.95	0.67	0.81	0.73
Working capital	87.46M	78.68M	71.03M	76.76M	94.06M
Tangible asset value	75.93M	64.84M	54.78M	53.71M	106.89M
Net current asset value	60.24M	53.96M	44.25M	48.83M	55.71M
Invested capital	0.09	0.1	0.11	0.11	0.05
Average receivables	1.02M	1.47M	1.98M	2.54M	26.84M
Average payables	1.6M	600K	946.5K	1.21M	1.24M
Average inventory	-2.23M	-2.23M	0	0	0
Days sales outstanding	2.11	226.82	238.48	10.56	63.52
Days payables outstanding	153.82	5.84	12.4	919.17	3.26K
Days of inventory on hand	-1.11K	0	0	0	0
Receivables turnover	42.71	0.4	0.38	8.52	1.42
Payables turnover	0.59	15.4	7.26	0.1	0.03
Inventory turnover	-0.08	0	0	0	0
ROE	0.35	-0.19	-0.22	-0.06	0.48
Capex per share	0	0	0	0	0

SPRO Frequently Asked Questions

What is Spero Therapeutics, Inc. stock symbol ?

Spero Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol SPRO

What is Spero Therapeutics, Inc. stock quote today ?

Spero Therapeutics, Inc. stock price is $1.41 today.

Is Spero Therapeutics, Inc. stock public?

Yes, Spero Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 317.01K
Market Capitalization 88.35M
Employee 46
CEO Mr. Satyavrat Shukla C.F.A.
Headquarters Cambridge,MA,US
IPO Date 2017-11-02
Website https://sperotherapeutics.com

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.